Ceftriaxone: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 14: | Line 14: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Ceftriaxone description|Description]]''' | ''' [[Ceftriaxone description|Description]]''' | ||
'''| [[Ceftriaxone clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Ceftriaxone clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Ceftriaxone microbiology|Microbiology]]''' | '''| [[Ceftriaxone microbiology|Microbiology]]''' | ||
| Line 27: | Line 27: | ||
'''| [[Ceftriaxone how supplied|How Supplied]]''' | '''| [[Ceftriaxone how supplied|How Supplied]]''' | ||
'''| [[Ceftriaxone labels and packages|Labels and Packages]]''' | '''| [[Ceftriaxone labels and packages|Labels and Packages]]''' | ||
==References== | ==References== | ||
Revision as of 19:13, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Ceftriaxone is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to cefotaxime in terms of safety and efficacy. Ceftriaxone sodium is marketed by Hoffman-La Roche under the trade name Rocephin.
Category
Cephalosporins, Third-Generation
US Brand Names
CEFTRIAXONE®, ROCEPHIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility and Stability | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/050796lbl.pdf